- Home
- COEP vs ACXP Comparison
COEP vs ACXP Comparison
Compare COEP & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- ACXP
- Stock Information
- Founded
- COEP 2017
- ACXP 2017
- Country
- COEP United States
- ACXP United States
- Employees
- COEP N/A
- ACXP N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- ACXP Health Care
- Exchange
- COEP Nasdaq
- ACXP Nasdaq
- Market Cap
- COEP 27.4M
- ACXP 8.4M
- IPO Year
- COEP N/A
- ACXP 2021
- Fundamental
- Price
- COEP $10.66
- ACXP $0.45
- Analyst Decision
- COEP
- ACXP Strong Buy
- Analyst Count
- COEP 0
- ACXP 2
- Target Price
- COEP N/A
- ACXP $10.00
- AVG Volume (30 Days)
- COEP 45.5K
- ACXP 1.1M
- Earning Date
- COEP 08-15-2025
- ACXP 08-08-2025
- Dividend Yield
- COEP N/A
- ACXP N/A
- EPS Growth
- COEP N/A
- ACXP N/A
- EPS
- COEP N/A
- ACXP N/A
- Revenue
- COEP $62,874.00
- ACXP N/A
- Revenue This Year
- COEP N/A
- ACXP N/A
- Revenue Next Year
- COEP N/A
- ACXP N/A
- P/E Ratio
- COEP N/A
- ACXP N/A
- Revenue Growth
- COEP N/A
- ACXP N/A
- 52 Week Low
- COEP $2.31
- ACXP $0.30
- 52 Week High
- COEP $13.70
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- COEP 65.93
- ACXP 48.12
- Support Level
- COEP $7.25
- ACXP $0.40
- Resistance Level
- COEP $11.70
- ACXP $0.46
- Average True Range (ATR)
- COEP 0.67
- ACXP 0.06
- MACD
- COEP 0.35
- ACXP -0.01
- Stochastic Oscillator
- COEP 76.81
- ACXP 26.88
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.